CN104169305B - 制备多糖纳米粒的方法 - Google Patents

制备多糖纳米粒的方法 Download PDF

Info

Publication number
CN104169305B
CN104169305B CN201380014214.8A CN201380014214A CN104169305B CN 104169305 B CN104169305 B CN 104169305B CN 201380014214 A CN201380014214 A CN 201380014214A CN 104169305 B CN104169305 B CN 104169305B
Authority
CN
China
Prior art keywords
nanoparticle
oxidation
polysaccharide
amino
aldehyde radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380014214.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104169305A (zh
Inventor
托马斯·凯驰
伊加·瓦斯阿克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanovelos SpZOO
Original Assignee
Nanovelos SpZOO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanovelos SpZOO filed Critical Nanovelos SpZOO
Publication of CN104169305A publication Critical patent/CN104169305A/zh
Application granted granted Critical
Publication of CN104169305B publication Critical patent/CN104169305B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B1/00—Preparatory treatment of cellulose for making derivatives thereof, e.g. pre-treatment, pre-soaking, activation
    • C08B1/08—Alkali cellulose
    • C08B1/10—Apparatus for the preparation of alkali cellulose
    • C08B1/12—Steeping devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B11/00—Preparation of cellulose ethers
    • C08B11/02—Alkyl or cycloalkyl ethers
    • C08B11/04—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals
    • C08B11/10—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals substituted with acid radicals
    • C08B11/12—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals substituted with acid radicals substituted with carboxylic radicals, e.g. carboxymethylcellulose [CMC]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/08—Cellulose derivatives
    • C08L1/26—Cellulose ethers
    • C08L1/28—Alkyl ethers
    • C08L1/286—Alkyl ethers substituted with acid radicals, e.g. carboxymethyl cellulose [CMC]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/02—Dextran; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B1/00—Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201380014214.8A 2012-03-14 2013-03-12 制备多糖纳米粒的方法 Active CN104169305B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PLPL398450 2012-03-14
PL398450 2012-03-14
PL398450A PL221351B1 (pl) 2012-03-14 2012-03-14 Sposób otrzymywania nanocząstek polisacharydowych
PCT/PL2013/000030 WO2013137755A1 (en) 2012-03-14 2013-03-12 Process for the preparation of polysaccharide nanoparticles

Publications (2)

Publication Number Publication Date
CN104169305A CN104169305A (zh) 2014-11-26
CN104169305B true CN104169305B (zh) 2016-07-27

Family

ID=48014274

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380014214.8A Active CN104169305B (zh) 2012-03-14 2013-03-12 制备多糖纳米粒的方法

Country Status (14)

Country Link
US (1) US10258579B2 (cg-RX-API-DMAC7.html)
EP (1) EP2825563B1 (cg-RX-API-DMAC7.html)
JP (1) JP6470169B2 (cg-RX-API-DMAC7.html)
CN (1) CN104169305B (cg-RX-API-DMAC7.html)
AU (1) AU2013232850B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014022767B1 (cg-RX-API-DMAC7.html)
CA (1) CA2866682C (cg-RX-API-DMAC7.html)
ES (1) ES2780387T3 (cg-RX-API-DMAC7.html)
IL (1) IL234572A (cg-RX-API-DMAC7.html)
IN (1) IN2014MN01651A (cg-RX-API-DMAC7.html)
MX (1) MX369114B (cg-RX-API-DMAC7.html)
PL (1) PL221351B1 (cg-RX-API-DMAC7.html)
RU (1) RU2632019C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013137755A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6640736B2 (ja) * 2014-12-12 2020-02-05 日本化薬株式会社 核酸代謝拮抗剤が結合した多分岐化合物
CA3032635A1 (en) * 2016-08-01 2018-02-08 Hppe, Llc Biopolymers for fugitive dust control
US10736964B2 (en) * 2017-05-01 2020-08-11 China Medical University Immunomagnetic nanocapsule and kit for treating cancer
CN107446054B (zh) * 2017-08-11 2021-05-18 武汉理工大学 一种生物质基纳米粒子及其制备方法和应用
PL424773A1 (pl) * 2018-03-06 2019-09-09 Nanovelos Spółka Akcyjna Enkapsulowana polisacharydem antracyklina do zastosowania w leczeniu nowotworów
CN108676181B (zh) * 2018-05-30 2022-05-17 江西师范大学 通过二醛基纤维素制备纤维素纳米颗粒的方法
CN108553448A (zh) * 2018-05-30 2018-09-21 江西师范大学 一种pH响应的药物缓释纤维素纳米颗粒的制备方法
PL240772B1 (pl) 2018-06-11 2022-06-06 Nanothea Spolka Akcyjna Sposób wytwarzania nanocząstek polimerowych chelatujących izotopy promieniotwórcze do zastosowania w diagnostyce i terapii
CN112353781B (zh) * 2020-11-12 2022-08-19 云南开放大学 一种药物载体空心纳米球的制备方法
CN112516310B (zh) * 2020-12-11 2022-11-29 武汉理工大学 一种肿瘤酸环境响应的纳米前药的制备方法及其应用
CN112830979A (zh) * 2021-01-15 2021-05-25 江南大学 一种改性黄原胶及其制备方法与应用
CN113800501B (zh) * 2021-10-08 2023-04-18 山西大学 一种用于检测pH和精氨酸的橙红色荧光碳点的制备方法及其应用
WO2023092208A1 (pt) * 2021-11-25 2023-06-01 Universidade Estadual De Campinas Processo de obtenção de solução polimérica injetável fotoreticulável, solução polimérica injetável fotoreticulável e seus usos
CN115463262B (zh) * 2022-08-11 2024-06-04 南方医科大学第五附属医院 一种水凝胶复合修复补片及其制备方法与应用
CN117898426A (zh) * 2023-12-05 2024-04-19 江苏蓝果临床营养科技有限公司 一种调节肠道功能紊乱的纳米颗粒及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1596129A (zh) * 2001-06-21 2005-03-16 费森尤斯卡比德国有限公司 多糖结合物形式的含有氨基糖的水溶性抗生素
CN1638808A (zh) * 2002-03-06 2005-07-13 弗雷泽纽斯卡比德国有限公司 蛋白质与修饰多糖的偶联
CN101273066A (zh) * 2005-09-09 2008-09-24 罗在云 用于递送抗癌剂的水溶性壳聚糖纳米颗粒及其制备方法
WO2011069475A2 (en) * 2009-12-11 2011-06-16 Contipro C A.S. A method of preparation of an oxidized derivative of hyaluronic acid and a method of modification thereof
WO2012004007A1 (en) * 2010-07-09 2012-01-12 Fresenius Kabi Deutschland Gmbh Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU825542A1 (ru) * 1979-04-04 1981-04-30 Inst Orch Chimii Aka Способ получения n-производных полисахаридов 1
US4452773A (en) * 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4693912A (en) * 1985-02-28 1987-09-15 Technicon Instruments Corporation Lyophilization of reagent-coated particles
US4699784A (en) * 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
JPS62221637A (ja) * 1986-03-24 1987-09-29 Green Cross Corp:The 制癌剤−抗体複合体の製造方法
JPS62283101A (ja) * 1986-05-30 1987-12-09 Green Cross Corp:The 制癌作用物質複合体の製造方法
JPS63264427A (ja) * 1986-12-17 1988-11-01 Green Cross Corp:The 制癌作用物質複合体
JPH01190636A (ja) * 1988-01-22 1989-07-31 Green Cross Corp:The 制癌作用物質複合体
EP0999222A1 (en) 1998-11-02 2000-05-10 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Carbohydrate oxidation products
SK288117B6 (sk) * 1998-11-20 2013-09-03 Skyepharma Canada Inc. Rapidly dispersing solid dry therapeutic dosage form
IL131074A0 (en) * 1999-07-23 2001-03-19 Polygene Ltd A biodegradable polycation composition for delivery of an anionic macromolecule
BR0112287A (pt) 2000-06-29 2003-05-06 Daiichi Seiyaku Co Composto dds e seu método de preparação
TWI313609B (en) 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
JP2005535604A (ja) * 2002-06-03 2005-11-24 アルニス バイオサイエンシーズ, インコーポレイテッド 治療剤を含むポリマーナノ物品
KR100578382B1 (ko) * 2004-07-16 2006-05-11 나재운 항암제의 전달체용 수용성 키토산 나노입자 및 그 제조방법
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
KR101465994B1 (ko) * 2005-05-27 2014-11-27 로이어 바이오메디칼 인코포레이티드 생체재흡수성 중합체 매트릭스 및 이의 제조방법과 사용방법
WO2007023386A2 (en) 2005-08-24 2007-03-01 Novartis Vaccines And Diagnostics Srl Zwitterionization of capsular saccharides
EP1926498A2 (en) * 2005-09-22 2008-06-04 Hadasit Medical Research Services And Development Company Ltd. Dextran and arabinogalactan conjugates of therapeutically active compounds
US8563066B2 (en) * 2007-12-17 2013-10-22 New World Pharmaceuticals, Llc Sustained release of nutrients in vivo
CN102361655B (zh) * 2008-11-19 2016-08-03 阿克塔马克斯手术器材有限责任公司 纤维组织封合剂及其使用方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1596129A (zh) * 2001-06-21 2005-03-16 费森尤斯卡比德国有限公司 多糖结合物形式的含有氨基糖的水溶性抗生素
CN1638808A (zh) * 2002-03-06 2005-07-13 弗雷泽纽斯卡比德国有限公司 蛋白质与修饰多糖的偶联
CN101273066A (zh) * 2005-09-09 2008-09-24 罗在云 用于递送抗癌剂的水溶性壳聚糖纳米颗粒及其制备方法
WO2011069475A2 (en) * 2009-12-11 2011-06-16 Contipro C A.S. A method of preparation of an oxidized derivative of hyaluronic acid and a method of modification thereof
WO2012004007A1 (en) * 2010-07-09 2012-01-12 Fresenius Kabi Deutschland Gmbh Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation

Also Published As

Publication number Publication date
IN2014MN01651A (cg-RX-API-DMAC7.html) 2015-05-29
PL398450A1 (pl) 2013-09-16
MX2014010979A (es) 2015-02-24
EP2825563B1 (en) 2020-02-05
EP2825563A1 (en) 2015-01-21
RU2632019C2 (ru) 2017-10-02
US20150072946A1 (en) 2015-03-12
RU2014133962A (ru) 2016-03-20
CA2866682C (en) 2016-05-17
BR112014022767B1 (pt) 2021-08-31
PL221351B1 (pl) 2016-03-31
MX369114B (es) 2019-10-29
JP6470169B2 (ja) 2019-02-13
BR112014022767A2 (cg-RX-API-DMAC7.html) 2017-10-03
ES2780387T3 (es) 2020-08-25
US10258579B2 (en) 2019-04-16
AU2013232850A1 (en) 2014-09-11
CA2866682A1 (en) 2013-09-19
AU2013232850B2 (en) 2016-01-07
JP2015514059A (ja) 2015-05-18
WO2013137755A1 (en) 2013-09-19
CN104169305A (zh) 2014-11-26
IL234572A (en) 2017-01-31

Similar Documents

Publication Publication Date Title
CN104169305A (zh) 制备多糖纳米粒的方法
Tao et al. Albumin conjugates and assemblies as versatile bio-functional additives and carriers for biomedical applications
Basu et al. Polysaccharide-based conjugates for biomedical applications
Luan et al. Self‐assembled peptide‐based nanodrugs: molecular design, synthesis, functionalization, and targeted tumor bioimaging and biotherapy
Saravanakumar et al. Polysaccharide-based nanoparticles: a versatile platform for drug delivery and biomedical imaging
Della Sala et al. Advances in hyaluronic‐acid‐based (nano) devices for cancer therapy
Li et al. Chemical modification of chitosan for developing cancer nanotheranostics
CN103212083B (zh) 一种制备稳定的白蛋白纳米颗粒的方法
Kang et al. pH-sensitive fluorescent hyaluronic acid nanogels for tumor-targeting and controlled delivery of doxorubicin and nitric oxide
Yao et al. Dual-functional carbon dot-labeled heavy-chain ferritin for self-targeting bio-imaging and chemo-photodynamic therapy
Youn et al. Multifunctional nano-sized fullerenes for advanced tumor therapy
CN110801431B (zh) 一种核-壳型智能纳米递送系统的构建及应用
CA2506842A1 (en) Amplification of biotin-mediated targeting
Ghassami et al. Redox sensitive polysaccharide based nanoparticles for improved cancer treatment: a comprehensive review
KR20130131227A (ko) 금속 나노 입자 기반 간 표적 지향 약물 전달체 및 이의 제조방법
Singh et al. Polysaccharides as nanocarriers for therapeutic applications
Beiranvand et al. An analytical review of the therapeutic application of recent trends in MIL-based delivery systems in cancer therapy
Jang et al. Hyaluronic acid-siRNA conjugate/reducible polyethylenimine complexes for targeted siRNA delivery
CN104162166B (zh) pH敏感性多糖纳米载药胶束及其制备方法
Feng et al. Natural hydrogels applied in photodynamic therapy
CN103816547A (zh) 一种主动靶向的靶向多肽修饰的壳聚糖载体材料及其制备方法
Zhang et al. Supramolecular in situ assemblage and its biological applications
Maghsoudnia et al. Hyaluronic acid in drug delivery
Abid et al. Recent advancement and developments in biomaterial-based nanomedicines, imaging, and cures
CN115089731B (zh) 一种协同化疗与光热治疗的纳米药物递送系统及其制备方法与应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant